BRPI0905681A2 - "análogos da prolina como ligantes para receptores de canabinóide" - Google Patents

"análogos da prolina como ligantes para receptores de canabinóide"

Info

Publication number
BRPI0905681A2
BRPI0905681A2 BRPI0905681-5A BRPI0905681A BRPI0905681A2 BR PI0905681 A2 BRPI0905681 A2 BR PI0905681A2 BR PI0905681 A BRPI0905681 A BR PI0905681A BR PI0905681 A2 BRPI0905681 A2 BR PI0905681A2
Authority
BR
Brazil
Prior art keywords
receptor ligands
cannabinoid receptor
proline analogs
proline
analogs
Prior art date
Application number
BRPI0905681-5A
Other languages
English (en)
Inventor
Yao
Jiangchao
Shao
Bin
Original Assignee
Purdue Pharma Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp
Publication of BRPI0905681A2 publication Critical patent/BRPI0905681A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0905681-5A 2008-01-08 2009-01-08 "análogos da prolina como ligantes para receptores de canabinóide" BRPI0905681A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1044708P 2008-01-08 2008-01-08
PCT/IB2009/000023 WO2009087564A1 (en) 2008-01-08 2009-01-08 Proline analogs as ligands for cannabinoid receptors for the treatment of pain

Publications (1)

Publication Number Publication Date
BRPI0905681A2 true BRPI0905681A2 (pt) 2015-07-07

Family

ID=40474987

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0905681-5A BRPI0905681A2 (pt) 2008-01-08 2009-01-08 "análogos da prolina como ligantes para receptores de canabinóide"

Country Status (14)

Country Link
US (1) US8084612B2 (pt)
EP (2) EP2583963A1 (pt)
JP (1) JP5236748B2 (pt)
KR (1) KR101343399B1 (pt)
CN (1) CN101910126B (pt)
AU (1) AU2009203549B2 (pt)
BR (1) BRPI0905681A2 (pt)
CA (2) CA2794054C (pt)
HK (1) HK1146270A1 (pt)
IL (2) IL206355A0 (pt)
MX (1) MX2010007622A (pt)
NZ (1) NZ586094A (pt)
WO (1) WO2009087564A1 (pt)
ZA (1) ZA201004059B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2350548B1 (es) * 2009-06-25 2011-09-29 Institut Univ. De Ciència I Tecnologia, S.A. N-fenil-1-sulfonil-2-pirrolidinacarboxamidas para la identificacion de actividad biologica y farmacologica.
PT2565190E (pt) 2010-04-28 2015-08-24 Astellas Pharma Inc Composto de tetra-hidrobenzotiofeno
KR101802726B1 (ko) 2010-08-24 2017-11-29 액테리온 파마슈티칼 리미티드 오렉신 수용체 안타고니스트로서의 프롤린 술폰아미드 유도체
JP6020460B2 (ja) * 2011-10-27 2016-11-02 アステラス製薬株式会社 アミノアルキル置換n−チエニルベンズアミド誘導体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
ES2008634A6 (es) 1988-10-06 1989-07-16 Lilly Sa Un procedimiento para la produccion de derivados de tiofeno.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
GB9304156D0 (en) * 1992-03-26 1993-04-21 Zeneca Ltd Antibiotic compounds
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
DE69635048T2 (de) 1995-06-12 2006-02-16 G.D. Searle & Co. Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
GB9525262D0 (en) 1995-12-11 1996-02-07 Bayer Ag Heterocyclylcarbonyl substituted benzofuranyl-ureas
AU750175B2 (en) * 1997-11-24 2002-07-11 Merck & Co., Inc. Cyclic amino acid derivatives as cell adhesion inhibitors
ES2294330T3 (es) * 2002-08-02 2008-04-01 MERCK & CO., INC. Derivados de furo(2,3-b)piridina sustituidos.
US6852748B1 (en) * 2002-10-30 2005-02-08 Boehringer Ingelheim Pharmaceuticals, Inc. Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide
TW200602324A (en) * 2004-03-24 2006-01-16 Janssen Pharmaceutica Nv Tetrahydro-indazole cannabinoid modulators cross reference to related applications
SE0401342D0 (sv) * 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
JP4760139B2 (ja) * 2004-05-28 2011-08-31 田辺三菱製薬株式会社 ピロリジン誘導体およびその製法
CN1960970A (zh) * 2004-05-28 2007-05-09 田边制药株式会社 作为cb1受体的拮抗剂的吡咯烷衍生物
FR2880890B1 (fr) 2005-01-19 2007-03-30 Sanofi Aventis Sa Derives de n-[(4,5-diphenyl-2-thienyl)methyl]sulfonamide, leur preparation et leur application en therapeutique
JP2007262022A (ja) * 2006-03-29 2007-10-11 Mochida Pharmaceut Co Ltd 新規2−チオフェンカルボキサミド誘導体

Also Published As

Publication number Publication date
IL226799A0 (en) 2013-07-31
US8084612B2 (en) 2011-12-27
MX2010007622A (es) 2011-01-21
CN101910126B (zh) 2014-04-30
EP2240443B1 (en) 2013-11-20
AU2009203549A1 (en) 2009-07-16
KR20100113556A (ko) 2010-10-21
CA2711508C (en) 2013-07-16
WO2009087564A1 (en) 2009-07-16
JP2011509285A (ja) 2011-03-24
CA2794054A1 (en) 2009-07-16
US20090291947A1 (en) 2009-11-26
IL206355A0 (en) 2010-12-30
EP2240443A1 (en) 2010-10-20
KR101343399B1 (ko) 2013-12-19
AU2009203549B2 (en) 2013-03-07
ZA201004059B (en) 2011-05-25
EP2583963A1 (en) 2013-04-24
CN101910126A (zh) 2010-12-08
NZ586094A (en) 2012-06-29
JP5236748B2 (ja) 2013-07-17
HK1146270A1 (en) 2011-05-20
CA2711508A1 (en) 2009-07-16
CA2794054C (en) 2014-11-25

Similar Documents

Publication Publication Date Title
DK2587805T3 (da) Tilstandsensartethedssignalering til intra-kodning
BRPI0817562A2 (pt) derivados de n-hidroxilsulfonamida como novos doadores de niltroxil fisiologicamente úteis
BRPI0910229A2 (pt) Tetramatos de 4';4'-dioxaspiro espirociclicamente substituídos
BRPI0919135A2 (pt) compostos inéditos como ligantes do receptor canabinóide.
BRPI0815246A2 (pt) Composição de catalisador
BRPI0913806A2 (pt) "composição"
DE112009004699A5 (de) Elektrochirurgisches System
BRPI1008939A2 (pt) 2-mercaptoquinolina-3-carboxamidas substituídas como moduladores de kncq2/3.
DK2326651T3 (da) Buprenorphinanaloger
BRPI0922904A2 (pt) "compostos"
BR112012008159A2 (pt) moduladores de receptor canabinoide
BRPI1008899A2 (pt) derivados 3,3´-espiroindolinona como agentes anticâncer
FR2921069B1 (fr) Composition polyamide
BRPI0918064A2 (pt) distribuidor de substância
BRPI0919898A2 (pt) 4,5,6,7-tetra-hidrotienopiridinas substituídas como moduladores de kcnq2/3
CU23870B1 (es) Derivados de ciclopropilamida como moduladores h3
BRPI0814806A2 (pt) Pirazinas substituídas como antagonistas de cb1
BRPI1006632A2 (pt) composição catalisadora
BRPI0914063A2 (pt) composição de xampu concentrado
BRPI0909854A2 (pt) "arranjo de fracionamento"
BRPI0718436A2 (pt) Novos derivados de benzamida como antagonistas da bradicina
BRPI0918344A2 (pt) composição catalítica
BRPI0816624A2 (pt) Sapata de trilho ferroviário
BRPI1010198A2 (pt) composição de poliamida modificada
BR112012010203A2 (pt) composição catalisadora apoiada

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE. PAGAR RESTAURACAO.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2343 DE 01/12/2015.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements